POZEN signed two new agreements with GlaxoSmithKline (GSK) and Nycomed Danmark (ND). The first deal, with GSK, relates to the development and commercialization of MT-400, a combination of triptan and a long-acting NSAID. In the second agreement, ND has licensed exclusive rights to commercialize POZEN’s MT-100™.